The recommended lifestyle has beneficial associations with most cancers. In terms of absolute risk, the protective association is greater for higher genetic risk groups for some cancers. These findings have important implications for persons most genetically predisposed to those cancers and for targeted strategies for cancer prevention.
In summary, LS care has come a long way over the last twenty years. We now understand the individual cancer risk to inform consent, tests to accurately diagnoses LS and ways by which we can reduce cancer risk.
However, more needs to be done to find those who are undiagnosed, develop less invasive cancer surveillance methods and develop new vaccinations and treatments.
Lynch syndrome increases the risk of many different types of cancer, including ovarian cancer. The exact level of risk depends on which gene contains the mutation.
Overall, ovarian cancer is rare. The American Cancer SocietyTrusted Source estimates that 1 in 78 (1.2%) of people with ovaries will develop ovarian cancer during their lifetime. Additionally, more than half of people receive a diagnosis at age 63 or older.
In contrast, people with Lynch syndrome have a 3% to 17% lifetime risk of developing ovarian cancer. They also often develop cancer at a younger age than people without Lynch syndrome.
A biobank (“bank of life”) is a place – typically an ultralow temperature freezer – that stores blood and other human tissue samples donated by patients for research in cancer or other serious diseases. It is maintained by specialist personnel, and data is coded for the patient’s privacy and confidentiality, and recorded in a database. Clinical data, including treatment and follow-up, may be linked subsequently.
The patient’s cancer operation specimen – cancer and surrounding normal tissue – is examined by a Histopathologist. The pathological diagnosis and full pathological assessment of the tumour’s aggressiveness and extent determine the patient’s further treatment. Providing the patient has consented, small fragments of cancer and normal tissue, surplus to pathology requirements, may be coded, frozen and stored in the biobank. Samples are released for ethical, scientifically approved research on how cancers develop, grow, spread and respond to treatment.
The IMPACT trial is an international study looking at how well PSA (prostate-specific antigen) screening for prostate cancer works for people with inherited mutations. This report shared early results of screening in people with Lynch syndrome.
Initial results from the IMPACT trial show that PSA testing to screen for prostate cancer in people with Lynch syndrome can detect aggressive early prostate cancers. These findings support the use of PSA screening in men with Lynch syndrome, particularly men with an inherited mutation in an MSH2 or MSH6 gene.
Delivery of a comprehensive service for the detection of Lynch syndrome
Led by the North Thames and South East GMSAs, the NHS GMS National Lynch Syndrome project is working to improve the identification and management of Lynch Syndrome, bridging the gap in testing and diagnosis of Lynch Syndrome and supporting the early detection of cancer and access to personalised care.
The project will initially focus on colorectal and endometrial cancer patients and over time the programme will aim to extend LS screening across relevant tumour types.